Ivermectin: an award-winning drug with expected antiviral activity against COVID-19.
J Control Release
; 329: 758-761, 2021 01 10.
Article
en En
| MEDLINE
| ID: mdl-33038449
ABSTRACT
Ivermectin is an FDA-approved broad-spectrum antiparasitic agent with demonstrated antiviral activity against a number of DNA and RNA viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite this promise, the antiviral activity of ivermectin has not been consistently proven in vivo. While ivermectin's activity against SARS-CoV-2 is currently under investigation in patients, insufficient emphasis has been placed on formulation challenges. Here, we discuss challenges surrounding the use of ivermectin in the context of coronavirus disease-19 (COVID-19) and how novel formulations employing micro- and nanotechnologies may address these concerns.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Antivirales
/
Ivermectina
/
Portadores de Fármacos
/
Nanopartículas
/
SARS-CoV-2
/
Tratamiento Farmacológico de COVID-19
Tipo de estudio:
Clinical_trials
Límite:
Humans
Idioma:
En
Revista:
J Control Release
Asunto de la revista:
FARMACOLOGIA
Año:
2021
Tipo del documento:
Article